Search research articles
Contact Us
Filters
Showing results (61-70 of 104) with videos related to
Page
of 11
Sort By:
Open Forum Infectious Diseases
|
August 13, 2025
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona Cohort
Andrea Giacomelli, Simone Lanini, Andrea De Vito, et al.
Plos Pathogens
|
January 6, 2017
Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient
Mirella Biava, Claudia Caglioti, Licia Bordi, et al.
The Lancet. Infectious Diseases
|
April 18, 2015
Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?
Simone Lanini, Alimuddin Zumla, John P A Ioannidis, et al.
The Lancet. Infectious Diseases
|
August 28, 2019
Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials
Simone Lanini, John P A Ioannidis, Francesco Vairo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 20, 2025
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
Roberta Gagliardini, Marta Camici, Simone Lanini, et al.
Journal of Global Antimicrobial Resistance
|
July 6, 2022
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
Daniele Armenia, Federica Forbici, Ada Bertoli, et al.
The Lancet. Infectious Diseases
|
April 3, 2016
Non-randomised Ebola trials--lessons for optimal outbreak research
Giuseppe Ippolito, Simone Lanini, Philippe Brouqui, et al.
Journal of Medical Virology
|
May 25, 2023
Temporal intra-host variability of mpox virus genomes in multiple body tissues
Martina Rueca, Fabio Giovanni Tucci, Valentina Mazzotta, et al.
The Journal of Infection
|
November 8, 2022
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
Annalisa Mondi, Roberta Gagliardini, Valentina Mazzotta, et al.
Journal of Medical Virology
|
June 12, 2023
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox
Valentina Mazzotta, Alessandro Cozzi-Lepri, Simone Lanini, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 104) with videos related to
Sort By:
Page
of 11
Open Forum Infectious Diseases
|
August 13, 2025
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona Cohort
Andrea Giacomelli, Simone Lanini, Andrea De Vito, et al.
Plos Pathogens
|
January 6, 2017
Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient
Mirella Biava, Claudia Caglioti, Licia Bordi, et al.
The Lancet. Infectious Diseases
|
April 18, 2015
Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?
Simone Lanini, Alimuddin Zumla, John P A Ioannidis, et al.
The Lancet. Infectious Diseases
|
August 28, 2019
Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials
Simone Lanini, John P A Ioannidis, Francesco Vairo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 20, 2025
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
Roberta Gagliardini, Marta Camici, Simone Lanini, et al.
Journal of Global Antimicrobial Resistance
|
July 6, 2022
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
Daniele Armenia, Federica Forbici, Ada Bertoli, et al.
The Lancet. Infectious Diseases
|
April 3, 2016
Non-randomised Ebola trials--lessons for optimal outbreak research
Giuseppe Ippolito, Simone Lanini, Philippe Brouqui, et al.
Journal of Medical Virology
|
May 25, 2023
Temporal intra-host variability of mpox virus genomes in multiple body tissues
Martina Rueca, Fabio Giovanni Tucci, Valentina Mazzotta, et al.
The Journal of Infection
|
November 8, 2022
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
Annalisa Mondi, Roberta Gagliardini, Valentina Mazzotta, et al.
Journal of Medical Virology
|
June 12, 2023
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox
Valentina Mazzotta, Alessandro Cozzi-Lepri, Simone Lanini, et al.
Page
of 11